Competition assays indicated this complex is resulted from HIF1α interactions. In addition, site-directed mutagenesis of potential HIF1α binding sites diminished a DNA-protein complex. These findings suggest that CAIII is a hypoxia-regulated gene and valuable for targeting of prostate cancer tumors in hypoxic condition.Circular RNAs (circRNA) are a special kind of covalently closed single-stranded RNA molecules. They have been shown to control and coordinate various biological processes. Recent researches show that circRNAs are closely associated with numerous chronic human diseases. Identification of circRNA-disease associations will contribute towards diagnosing the pathogenesis of diseases. Experimental methods for finding the relation between the diseases and their causal circRNAs are difficult and time-consuming. So computational methods are of critical need for predicting the associations between circRNAs and various human diseases. In this study, we propose an ensemble approach AE-DNN, which relies on autoencoder and deep neural networks to predict new circRNA-disease relationships. We utilized circRNA sequence similarity, disease semantic similarity, and Gaussian interaction profile kernel similarities of circRNAs and diseases for feature construction. The constructed features are fed to a deep autoencoder, and the extracted compact, high-level features are fed to the deep neural network for association prediction. We conducted 5-fold and 10-fold cross-validation experiments to assess the performance; AE-DNN could achieve AUC scores of 0.9392 and 0.9431, respectively. Experimental results and case studies indicate the robustness of our model in circRNA-disease association prediction.Development of two-dimensional high-quality graphene monolayers has recently received great concern owing to their enormous applications in diverging fields including electronics, photonics, composite materials, paints and coatings, energy harvesting and storage, sensors and metrology, and biotechnology. As a result, various groups have successfully developed graphene layers on different substrates by using the chemical vapor deposition method and explored their physical properties. In this direction, we have focused on the state-of-the-art developments in the growth of graphene layers, and their functional applications in biotechnology. The review starts with the introduction, which contains outlines about the graphene and their basic characteristics. A brief history and inherent applications of graphene layers followed by recent developments in growth and properties are described. Then, the application of graphene layers in biodevices is reviewed. Finally, the review is summarized with perspectives and future challenges along with the scope for future technological applications.
DG is a herbal formula, containing the root of Salvia miltiorrhiza Bunge (Danshen) and the root of Pueraria lobate (Willd.) Ohwi (Gegen), has a history of usage in China for cardiovascular protection and anti-atherosclerosis.

The present study aims to determine the beneficial effect of DG on the hind-limb ischemia rat model which mimics peripheral arterial disease (PAD) and its vasodilative effect on isolated femoral artery.

The vasodilatory effects were assessed by contractile responses to DG in the isolated femoral artery and its underlying mechanisms were evaluated by the involvement of endothelium, potassium channel and calcium channel. For hind-limb ischemia study, treatment outcomes were assessed by evaluating hind-limb blood flow, functional limb recovery, muscle histology and angiogenesis.

Our results demonstrated positive dose-dependent vasodilatory response to DG via an endothelium-independent mechanism that involved inwardly rectifying K
channels and Ca
channels. We also demonstrated significant improvement in blood perfusion and micro-vessel density in the ischemic limb and positive effects in functional limb recovery.

In conclusion, our study supported the potential use of DG as a novel treatment for symptomatic PAD.
In conclusion, our study supported the potential use of DG as a novel treatment for symptomatic PAD.
The uses of medicinal plants have a long history and become one of the important sources of the health cares in Gaomi City, Shandong Province, China. However, limited studies have been done to identify these medicinal plant species and to scientifically document their associated traditional knowledge. Many species used by indigenous people could potentially represent a novel resource of medicine. Epigenetic inhibitor The study can aid in further investigations of modern pharmacology and planning of the wild species conservation.

The study aimed to investigate and record the medicinal plant taxa and their associated traditional knowledge in Gaomi City, China.

Field study was conducted from March 2018 to May 2019 with 184 residents of Gaomi City. Traditional medicinal plant specimens were collected from the field with the help of these residents and were identified and authenticated in the Herbarium of the School of Pharmacy, Binzhou Medical University. Ethnobotanical knowledge was collected by semi-structured face-to-face innot been comprehensively documented. The therapeutic uses of the documented medicinal plants will provide a basis for further pharmacological and phytochemical investigations. Additionally, the result of this study indicated that the elder people in Gaomi have more traditional knowledge of plant medicines than the younger ones.
People in Gaomi hold valuable knowledge about the use of medicinal plants; however, their knowledge has not been comprehensively documented. The therapeutic uses of the documented medicinal plants will provide a basis for further pharmacological and phytochemical investigations. Additionally, the result of this study indicated that the elder people in Gaomi have more traditional knowledge of plant medicines than the younger ones.
To investigate the effects of prior treatment and the predictors of early treatment response to romosozumab (ROMO) in patients with postmenopausal osteoporosis.

In this prospective, observational, multicenter study, 130 treatment-naïve patients (Naïve; n=37) or patients previously treated with bisphosphonates (BP; n=33), denosumab (DMAb; n=45), or teriparatide (TPTD; n=15) (age, 75.0years; T-scores of the lumbar spine [LS] -3.2 and femoral neck [FN] -2.9) were switched to ROMO based on their physician's decision. Bone mineral density (BMD) and serum bone turnover markers were evaluated for six months.

At six months, LS BMD changes were 13.6%, 7.5%, 3.6%, and 8.7% (P<.001 between groups) and FN BMD changes were 4.2%, 0.4%, 1.6%, and 1.5% (P=.16 between groups) for Naïve, BP, DMAb, and TPTD groups, respectively. Changes in N-terminal type I procollagen propeptide (PINP; μg/L) levels from baseline→one month were 72.7→139.0, 33.5→85.4, 30.4→54.3, and 98.4→107.4, and those of isoform 5b of tartrate-resistant acid phosphatase (TRACP-5b) (mU/dL) were 474.Epigenetic inhibitor